The weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep ...

Ro integrates Eli Lilly’s Zepbound single-dose vials into its platform, offering obesity treatment starting at $399/month. Patients receive diagnosis, prescription, and home delivery through an ...

Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's (LLY.N), opens new tab weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first ...

The Phase IIIb SURMOUNT-5 trial found that Eli Lilly’s Zepbound was more effective in promoting weight loss than Novo Nordisk’s Wegovy. Credit: Ciara Kimsey / Shutterstock. Following positive results ...

The FDA has approved Eli Lilly’s obesity treatment, Zepbound, for the management of moderate to severe obstructive sleep apnea in people with obesity. This marks the first time a medication has been ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

This time last year, people were still bickering about whether Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound represented a shortcut to losing weight or a medical breakthrough.

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Sleep apnea causes people to stop and start breathing repeatedly Zepbound is first drug approved by FDA to help treat it Two studies found that those who used it saw reduction in apnea events ...